购物车
您的购物车当前为空
别名 津利利尤单抗, 10-1074
Zinlirvimab (10-1074) 是一种人源化 IgG1-λ2 单克隆中和抗体,靶向 HIV-1 封套糖蛋白受体上的 gp120/CD4 接口,以有效防止病毒附着。Zinlirvimab (10-1074) 通过识别并结合特定的保守表位,抑制病毒进入宿主 CD4+ T 细胞的复杂过程,从而有效阻止 Human Immunodeficiency Virus 建立生产性和系统性感染。Zinlirvimab (10-1074) 通过专门的 Fc 区修饰展示了显著优化的药理特性和延长的半衰期,使其作为持续病毒抑制的长效制剂发挥作用。
Zinlirvimab (10-1074) 是一种人源化 IgG1-λ2 单克隆中和抗体,靶向 HIV-1 封套糖蛋白受体上的 gp120/CD4 接口,以有效防止病毒附着。Zinlirvimab (10-1074) 通过识别并结合特定的保守表位,抑制病毒进入宿主 CD4+ T 细胞的复杂过程,从而有效阻止 Human Immunodeficiency Virus 建立生产性和系统性感染。Zinlirvimab (10-1074) 通过专门的 Fc 区修饰展示了显著优化的药理特性和延长的半衰期,使其作为持续病毒抑制的长效制剂发挥作用。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,490 | 2-4周 | |
| 5 mg | ¥ 6,470 | 2-4周 | |
| 10 mg | ¥ 9,870 | 2-4周 |
| 产品描述 | Zinlirvimab (10-1074) is a humanized IgG1-λ2 monoclonal neutralizing antibody that targets the gp120/CD4 interface on the HIV-1 envelope glycoprotein receptor to effectively prevent viral attachment. Zinlirvimab (10-1074) inhibits the complex process of viral entry into host CD4+ T cells by recognizing and binding to specific conserved epitopes, thereby effectively preventing the Human Immunodeficiency Virus from establishing a productive and systemic infection. Zinlirvimab (10-1074) exhibits a remarkably optimized pharmacological profile with a significantly extended half-life through specialized Fc-region modifications, facilitating its role as a persistent agent for sustained viral suppression. |
| 靶点活性 | HIV-1:IC500.02 μg/mL (IC50), CD4-gp120:52.09 ng/mL (EC50) |
| 别名 | 津利利尤单抗, 10-1074 |
| 反应种属 | Human |
| 应用 | ELISA FACS Functional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 同型 | IgG1 |
| 偶联 | Unconjugated |
| 靶点 | gp120/Glycoprotein 120 |
| CAS No. | 2417213-75-1 |
| 存储 |
对于不同动物的给药剂量换算,您也可以参考 更多